GlassScriptPhysician profile
Beaula V Koduri
NPI 1972505311
$13,263.52
in general payments reported to CMS, 2019-2025
71 companies · $530 in 2025
The $530 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,971 · 2020: $1,484 · 2021: $2,145 · 2022: $2,851 · 2023: $2,548 · 2024: $1,734 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,029 · Education: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,028.91 |
| Education | $782.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,639.97 | 2019-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $1,211.42 | 2019-2024 | Opdivo, Opdualag, Krazati |
| Novartis Pharmaceuticals Corporation | $1,188.95 | 2019-2025 | |
| Janssen Biotech, INC. | $1,145.98 | 2019-2024 | Tecvayli, Darzalex, Talvey |
| Astellas Pharma US INC | $905.89 | 2020-2024 | |
| Pfizer INC. | $596.93 | 2019-2024 | |
| Amgen INC. | $516.99 | 2019-2025 | Vectibix, Nplate, Xgeva |
| Astrazeneca Pharmaceuticals LP | $480.34 | 2019-2024 | Enhertu, Brilinta, Lynparza |
| Gilead Sciences, INC. | $471.24 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $318.64 | 2019-2024 | Keytruda, Lynparza |
| Celgene Corporation | $284.32 | 2019-2023 | Reblozyl, Opdualag |
| Eisai INC. | $269.66 | 2019-2024 | |
| Genzyme Corporation | $260.49 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $257.27 | 2021-2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $235.02 | 2019-2024 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beaula Koduri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.